Galectin Therapeutics Company Profile (NASDAQ:GALT)

About Galectin Therapeutics

Galectin Therapeutics logoGalectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GALT
  • CUSIP:
Key Metrics:
  • Previous Close: $1.90
  • 50 Day Moving Average: $1.22
  • 200 Day Moving Average: $1.24
  • 52-Week Range: $0.49 - $3.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.18
  • P/E Growth: 0.00
  • Market Cap: $55.85M
  • Outstanding Shares: 29,396,000
  • Beta: 2.12
Profitability:
  • Return on Equity: -215.16%
  • Return on Assets: -103.03%
Debt:
  • Current Ratio: 3.95%
  • Quick Ratio: 3.95%
Additional Links:
Companies Related to Galectin Therapeutics:

Analyst Ratings

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings
Consensus Rating:Hold (Score: 1.67)
Consensus Price Target: $1.42 (25.44% downside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetDetails
2/6/2017FBR & CoReiterated RatingMarket Perform$2.00View Rating Details
9/29/2016HC WainwrightDowngradeBuy -> Neutral$8.00 -> $1.50View Rating Details
9/28/2016Roth CapitalReiterated RatingBuy -> Sell$3.00 -> $0.75View Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$16.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Galectin Therapeutics (NASDAQ:GALT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
8/9/2016Q2($0.24)($0.20)ViewN/AView Earnings Details
5/10/2016Q1($0.17)($0.24)ViewN/AView Earnings Details
3/15/2016Q415($0.22)($0.19)ViewListenView Earnings Details
11/9/2015Q3($0.20)($0.26)ViewN/AView Earnings Details
8/10/2015Q2($0.23)($0.21)ViewN/AView Earnings Details
5/11/2015Q115($0.20)($0.22)ViewN/AView Earnings Details
3/18/2015($0.17)($0.18)ViewN/AView Earnings Details
11/10/2014Q314($0.27)($0.17)ViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.17)ViewN/AView Earnings Details
5/13/2014Q114($0.20)($0.27)ViewN/AView Earnings Details
3/21/2014($0.18)($0.15)ViewN/AView Earnings Details
11/12/2013Q3($0.18)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.19)($0.18)ViewN/AView Earnings Details
5/10/2013Q1 2013($0.18)($0.22)ViewN/AView Earnings Details
11/9/2012Q312($0.18)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galectin Therapeutics (NASDAQ:GALT)
Current Year EPS Consensus Estimate: $-0.81 EPS
Next Year EPS Consensus Estimate: $-0.87 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.22)($0.22)($0.22)
Q2 20162($0.24)($0.22)($0.23)
Q3 20162($0.20)($0.20)($0.20)
Q4 20162($0.20)($0.16)($0.18)
Q1 20171($0.15)($0.15)($0.15)
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galectin Therapeutics (NASDAQ:GALT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galectin Therapeutics (NASDAQ:GALT)
Insider Ownership Percentage: 40.30%
Institutional Ownership Percentage: 10.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/5/2016Arthur GreenbergDirectorBuy1,666$1.72$2,865.52View SEC Filing  
8/12/2015Peter G TraberCEOBuy2,000$2.00$4,000.00View SEC Filing  
6/1/2015Kevin D FreemanDirectorBuy2,083$2.70$5,624.10View SEC Filing  
6/1/2015Peter G TraberCEOBuy4,000$2.53$10,120.00View SEC Filing  
8/19/2014Arthur GreenbergDirectorBuy1,000$4.56$4,560.00View SEC Filing  
8/15/2014Kevin D FreemanDirectorBuy1,000$4.70$4,700.00View SEC Filing  
8/14/2014Jack W CallicuttCFOBuy1,000$4.55$4,550.00View SEC Filing  
8/14/2014Peter G TraberCEOBuy4,000$4.46$17,840.00View SEC Filing  
8/13/2014Peter G TraberCEOBuy1,000$4.42$4,420.00View SEC Filing  
4/11/2014Steven PrelackDirectorSell6,000$11.84$71,040.00View SEC Filing  
1/13/2014James C CzirrChairmanSell100,000$14.84$1,484,000.00View SEC Filing  
12/4/2013Marc RubinDirectorBuy3,000$8.69$26,070.00View SEC Filing  
11/19/2013Arthur GreenbergDirectorBuy2,000$6.55$13,100.00View SEC Filing  
11/19/2013Peter G TraberCEOBuy1,000$5.53$5,530.00View SEC Filing  
11/18/2013Peter G TraberCEOBuy1,000$5.80$5,800.00View SEC Filing  
11/15/2013James C CzirrChairmanBuy1,000$6.90$6,900.00View SEC Filing  
6/3/2013John F MauldinDirectorBuy1,176$4.21$4,950.96View SEC Filing  
5/28/2013Kevin D FreemanDirectorBuy1,000$4.21$4,210.00View SEC Filing  
10/12/2012Peter G TraberCEOBuy2,500$2.11$5,275.00View SEC Filing  
10/9/2012Peter G TraberCEOBuy2,500$2.00$5,000.00View SEC Filing  
10/8/2012Peter G TraberCEOBuy5,000$2.07$10,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Galectin Therapeutics (NASDAQ:GALT)
DateHeadline
News IconInvestors are Looking at Levels for Galectin Therapeutics Inc (GALT) - The Standard (NASDAQ:GALT)
6milestandard.com - February 25 at 4:41 AM
News IconA Look Ahead For 2 Stocks: Galectin Therapeutics, Inc. (GALT ... - Post Analyst (NASDAQ:GALT)
postanalyst.com - February 25 at 4:41 AM
News IconGBI has new leads in case of teacher, beauty queen, missing 11+ (NASDAQ:GALT)
ekosvoice.com - February 23 at 10:21 PM
News IconRecent Price Move of Shares: Galectin Therapeutics Inc. (NASDAQ:GALT) (NASDAQ:GALT)
brassale.net - February 23 at 5:20 PM
News IconGalectin Therapeutics, Inc. (NASDAQ:GALT) has current Market Capitalization of $57020 (NASDAQ:GALT)
cloudhostinghq.net - February 23 at 3:38 AM
News IconVolatile Stock Causing a Fracas Mid-Session: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Aiken Advocate (NASDAQ:GALT)
aikenadvocate.com - February 22 at 5:35 PM
News IconUnusual Activity Sighted in Galectin Therapeutics, Inc. (NASDAQ:GALT) Shares - Winfield Review (NASDAQ:GALT)
winfieldreview.com - February 22 at 11:29 AM
marketexclusive.com logoGALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Amendments to Articles of Incorporation or Bylaws ... - Market Exclusive (NASDAQ:GALT)
marketexclusive.com - February 22 at 11:29 AM
4-traders.com logoGALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (NASDAQ:GALT)
www.4-traders.com - February 20 at 11:08 AM
4-traders.com logoGALECTIN THERAPEUTICS INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) (NASDAQ:GALT)
www.4-traders.com - February 18 at 12:30 PM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financ (NASDAQ:GALT)
biz.yahoo.com - February 18 at 12:30 PM
News IconGalectin Therapeutics, Inc. NASDAQ:GALT Volatility at Extreme Levels - Aiken Advocate (NASDAQ:GALT)
aikenadvocate.com - February 14 at 6:29 PM
News IconGalectin Therapeutics, Inc. (NASDAQ:GALT) Losing Traction Rapidly - Aiken Advocate (NASDAQ:GALT)
aikenadvocate.com - February 14 at 6:29 PM
News IconThe Galectin Therapeutics Inc. (GALT) Given $1.12 Consensus Target Price by Analysts (NASDAQ:GALT)
xboxonezone.com - February 10 at 10:59 PM
News IconStock Levels in Review for Galectin Therapeutics Inc. (GALT) - Davidson Register (NASDAQ:GALT)
davidsonregister.com - February 10 at 5:58 PM
News IconSince Election Day BioPharmaceutical Stocks Like Galectin Therapeutics Inc (NASDAQ:GALT) Have Recently Exploded - Street Register (NASDAQ:GALT)
streetregister.com - February 10 at 4:07 AM
istreetwire.com logoStocks Intraday Alert: The Manitowoc Company, Inc. (MTW), Galectin Therapeutics, Inc. (GALT), Spirit Airlines, Inc ... - iStreetWire (NASDAQ:GALT)
istreetwire.com - February 8 at 10:57 PM
globenewswire.com logoGalectin Therapeutics to Present at BIO CEO & Investor Conference - GlobeNewswire (press release) (NASDAQ:GALT)
globenewswire.com - February 8 at 10:57 PM
News IconE3 2017 opens to the public (NASDAQ:GALT)
xboxonezone.com - February 8 at 5:55 PM
biz.yahoo.com logoGALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:GALT)
us.rd.yahoo.com - February 8 at 5:55 PM
finance.yahoo.com logoGalectin Therapeutics to Present at BIO CEO & Investor Conference (NASDAQ:GALT)
finance.yahoo.com - February 8 at 5:55 PM
streetinsider.com logoGalectin Therapeutics (GALT) Says Combination with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical ... - StreetInsider.com (NASDAQ:GALT)
www.streetinsider.com - February 7 at 11:37 PM
News IconWatching Technical Levels on Shares of Galectin Therapeutics Inc. (GALT) - Rives Journal (NASDAQ:GALT)
rivesjournal.com - February 7 at 6:36 PM
feeds.benzinga.com logoCombination Immunotherapy with Galectin-3 Inhibitor GR-MD-02 Enhances Effects in Pre-clinical Models and Early Results of Phase 1 Clinical Trials (NASDAQ:GALT)
feeds.benzinga.com - February 7 at 5:48 PM
finance.yahoo.com logoGalectin Therapeutics Presentation Now Available for On-Demand Viewing - Yahoo Finance (NASDAQ:GALT)
finance.yahoo.com - February 6 at 5:23 PM
streetinsider.com logoGalectin Therapeutics Inc. (GALT) Sufficiently Positioned to Advance the NASH-CX Trial – FBR - StreetInsider.com (NASDAQ:GALT)
www.streetinsider.com - February 6 at 5:23 PM
marketexclusive.com logoGALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:GALT)
marketexclusive.com - February 2 at 5:53 PM
finance.yahoo.com logoGalectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 - Yahoo Finance (NASDAQ:GALT)
finance.yahoo.com - February 1 at 11:02 PM
baystreet.ca logoGelectin Therapeutics Reaches NASH-CX Trial Milestones - Baystreet.ca (NASDAQ:GALT)
www.baystreet.ca - February 1 at 11:02 PM
streetinsider.com logoGalectin Therapeutics (GALT) Says it Generated Sufficient Financing to Cover Currently Planned Expenditures ... - StreetInsider.com (NASDAQ:GALT)
www.streetinsider.com - February 1 at 11:02 PM
baystreet.ca logoGelectin Therapeutics Reaches NASH-CX Trial Milestones (NASDAQ:GALT)
www.baystreet.ca - February 1 at 6:01 PM
streetinsider.com logoGalectin Therapeutics (GALT) Says it Generated Sufficient Financing to Cover Currently Planned Expenditures Through 2017 (NASDAQ:GALT)
www.streetinsider.com - February 1 at 6:01 PM
us.rd.yahoo.com logo8:05 am Galectin Therapeutics says has generated sufficient financing to cover currently planned expenditures through 2017, remains on track to present top line data from its NASH-CX Phase 2 clinical trial by early December 2017. (NASDAQ:GALT)
us.rd.yahoo.com - February 1 at 6:01 PM
finance.yahoo.com logoGalectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial (NASDAQ:GALT)
finance.yahoo.com - February 1 at 6:01 PM
News IconWhat are the Levels Showing for Shares of Galectin Therapeutics Inc. (GALT) - Sherwood Daily (NASDAQ:GALT)
sherwooddaily.com - January 31 at 3:16 PM
News IconAt the Focal Point, Checking in on Galectin Therapeutics, Inc. (NASDAQ:GALT) - Prospect Journal (NASDAQ:GALT)
prospectjournal.com - January 31 at 3:16 PM
finance.yahoo.com logoGalectin Therapeutics to Webcast, Live, at VirtualInvestorConferences.com on February 2 (NASDAQ:GALT)
finance.yahoo.com - January 30 at 11:53 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Galectin Therapeutics, Inc. (NASDAQ:GALT) - Nelson Research (NASDAQ:GALT)
nelsonobserver.com - January 29 at 10:26 PM
News IconStock Update on Earnings & Estimates for Galectin Therapeutics Inc ... - Aiken Advocate (NASDAQ:GALT)
aikenadvocate.com - January 29 at 10:26 PM
News IconTechnical Action Update on Shares of Galectin Therapeutics Inc. (GALT) - Sherwood Daily (NASDAQ:GALT)
sherwooddaily.com - January 26 at 6:44 PM
News IconShares in View: Galectin Therapeutics Inc. (GALT) - Sherwood Daily (NASDAQ:GALT)
sherwooddaily.com - January 25 at 9:39 PM
einnews.com logoGalectin 1 Market & Interleukin 15 Industry Therapeutics Development Analysis Research Report (NASDAQ:GALT)
uspolitics.einnews.com - January 25 at 4:37 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Wall Street Beacon (NASDAQ:GALT)
wsbeacon.com - January 22 at 5:13 PM
News IconWhat are Brokerage Firms Saying About Galectin Therapeutics Inc. (NASDAQ:GALT)? - Aiken Advocate (NASDAQ:GALT)
aikenadvocate.com - January 22 at 5:13 PM
News IconSorting Out the Technicals on Shares of Galectin Therapeutics Inc. (GALT) - Sherwood Daily (NASDAQ:GALT)
sherwooddaily.com - January 20 at 12:07 AM
finance.yahoo.com logoPipeline Melanoma Market Global Review Research for H2 2016 (NASDAQ:GALT)
finance.yahoo.com - January 19 at 7:05 PM
News IconFollowing the Charts on Shares of Galectin Therapeutics Inc. (GALT) - Sherwood Daily (NASDAQ:GALT)
sherwooddaily.com - January 19 at 3:50 AM
News IconAre There Any Catalysts to Propel Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) - Prospect Journal (NASDAQ:GALT)
prospectjournal.com - January 19 at 3:50 AM
News IconAre Institutions Trimming Down Their Positions In Galectin Therapeutics, Inc. (NASDAQ:GALT) - Wall Street Beacon (NASDAQ:GALT)
wsbeacon.com - January 19 at 3:50 AM
News IconWith Profitability At The Forefront, Is This Stock a Top Pick: Galectin Therapeutics, Inc. (NASDAQ:GALT) - Wall Street Beacon (NASDAQ:GALT)
wsbeacon.com - January 17 at 7:58 AM

Social

What is Galectin Therapeutics' stock symbol?

Galectin Therapeutics trades on the NASDAQ under the ticker symbol "GALT."

Where is Galectin Therapeutics' stock going? Where will Galectin Therapeutics' stock price be in 2017?

3 brokerages have issued 12-month price objectives for Galectin Therapeutics' stock. Their forecasts range from $0.75 to $2.00. On average, they anticipate Galectin Therapeutics' share price to reach $1.42 in the next twelve months.

When will Galectin Therapeutics announce their earnings?

Galectin Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

What are analysts saying about Galectin Therapeutics stock?

Here are some recent quotes from research analysts about Galectin Therapeutics stock:

  • According to Zacks Investment Research, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (1/16/2017)

  • HC Wainwright analysts commented, "Be All, End All" (9/29/2016)

Who owns Galectin Therapeutics stock?

Galectin Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Richard E Uihlein (7.89%). Company insiders that own Galectin Therapeutics stock include Arthur Greenberg, James C Czirr, Kevin D Freeman and Peter G Traber.

How do I buy Galectin Therapeutics stock?

Shares of Galectin Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Galectin Therapeutics stock cost?

One share of Galectin Therapeutics stock can currently be purchased for approximately $1.90.

Galectin Therapeutics (NASDAQ:GALT) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Earnings History Chart

Earnings by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Dividend History Chart

Dividend Payments by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Last Updated on 2/25/2017 by MarketBeat.com Staff